Distribution of High-risk Human Papillomavirus Genotype Prevalence and Attribution to Cervical Precancerous Lesions in Rural North China

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2019 Oct 1

PMID 31564809

Citations 11

Authors

Shuang Zhao

Xuelian Zhao

Shangying Hu

Jessica Lu

Xianzhi Duan

Xun Zhang

Feng Chen

Fanghui Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: Precise prevention is more desired for cervical cancer due to the huge population, high prevalence of human papillomavirus (HPV) infection in China and the vision of screen-and-treat strategies in low- and middle-income countries (LMICs). Considerations of combining type-specific prevalence and attribution proportion to high-grade cervical intraepithelial neoplasia are informative to more precise and effective region-specific cervical cancer prevention and control programs. The aim of the current study was to determine the genotype distribution of HPV and attribution to cervical precancerous lesions among women from rural areas in North China.

Methods: A total of 9,526 women participated in the cervical cancer screening project in rural China. The samples of women who tested positive for HPV were retested with a polymerase chain reaction (PCR)-based HPV genotyping test. The attribution proportion of specific high-risk human papillomavirus (HR-HPV) types for different grades of cervical lesions was calculated by using the type contribution weighting method.

Results: A total of 22.2% (2,112/9,526) of women were HR-HPV positive and HPV52 (21.7%) was the most common HR-HPV genotype, followed by HPV58 (18.2%), HPV53 (18.2%) and HPV16 (16.2%). The top three genotypes detected in HR-HPV-positive cervical intraepithelial neoplasia (CIN)1 were HPV16 (36.7%), HPV58 (20.4%), HPV56 (15.3%). Among CIN2+, the most frequent genotypes were HPV16 (75.6%), HPV52 (17.8%), HPV58 (16.7%). HPV16, 56, 58, 53, 52, 59, 68, and 18 combined were attributed to 84.17% of all CIN1 lesions, and HPV16, 58, and 52 combined were attributed to 86.98% of all CIN2+ lesions.

Conclusions: The prevalence of HR-HPV infection among women from rural areas in North China was high and HPV16, HPV58, HPV52 had paramount attributable fraction in CIN2+. Type-specific HPV prevalence and attribution proportion to cervical precancerous lesions should be taken into consideration in the development of vaccines and strategy for screening in this population.

Citing Articles

Influence of COVID-19 pandemic on prevalence and genotype distribution of HPV in cervical cancer screening population.

Zhang H, Li X, Yang Z, Gao R, Chen B, Li S Virol J. 2024; 21(1):261.

PMID: 39443958 PMC: 11515561. DOI: 10.1186/s12985-024-02497-6.

Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women.

Huang M, Wang T, Li M, Qin M, Deng S, Chen D BMC Cancer. 2024; 24(1):913.

PMID: 39080593 PMC: 11287924. DOI: 10.1186/s12885-024-12696-7.

Distribution of HPV types among women with HPV-related diseases and exploration of lineages and variants of HPV 52 and 58 among HPV-infected patients in China: A systematic literature review.

Wang M, Liang H, Yan Y, Bian R, Huang W, Zhang X Hum Vaccin Immunother. 2024; 20(1):2343192.

PMID: 38745409 PMC: 11789740. DOI: 10.1080/21645515.2024.2343192.

Prevalence and genotype distribution of human papillomavirus infection among women in Jingzhou, China: a population-based study of 51,720 women.

Liu S, Mei B, Ouyang Y, Li C Virol J. 2023; 20(1):297.

PMID: 38102627 PMC: 10722767. DOI: 10.1186/s12985-023-02262-1.

Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis.

Zhao M, Zhou D, Zhang M, Kang P, Cui M, Zhu L PeerJ. 2023; 11:e16247.

PMID: 38025679 PMC: 10655709. DOI: 10.7717/peerj.16247.

References

De Vincenzo R, Ricci C, Conte C, Scambia G . HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol. 2013; 130(3):642-51. DOI: 10.1016/j.ygyno.2013.05.033. View

Zhao F, Lewkowitz A, Hu S, Chen F, Li L, Zhang Q . Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012; 131(12):2929-38. PMC: 3435460. DOI: 10.1002/ijc.27571. View

Zhao X, Hu S, Zhang Q, Dong L, Feng R, Han R . High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. J Gynecol Oncol. 2017; 28(4):e30. PMC: 5447139. DOI: 10.3802/jgo.2017.28.e30. View

Munoz N, Bosch F, Castellsague X, Diaz M, de Sanjose S, Hammouda D . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111(2):278-85. DOI: 10.1002/ijc.20244. View

Herrero R . Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis. 2009; 199(7):919-22. DOI: 10.1086/597308. View

Krul E, van de Vijver M, Schuuring E, Van Kanten R, Peters A, Fleuren G . Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. Int J Gynecol Cancer. 2001; 9(3):206-211. DOI: 10.1046/j.1525-1438.1999.99020.x. View

Health Commission Of The Peoples Republic Of China N . Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version). Chin J Cancer Res. 2019; 31(2):295-305. PMC: 6513737. DOI: 10.21147/j.issn.1000-9604.2019.02.04. View

de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N . Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7):453-9. DOI: 10.1016/S1473-3099(07)70158-5. View

Dong L, Feng R, Zhang L, Xu X, Zhao X, Wang M . Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China. J Gynecol Oncol. 2017; 28(5):e66. PMC: 5540725. DOI: 10.3802/jgo.2017.28.e66. View

10.

Zhao R, Zhang W, Wu M, Zhang S, Pan J, Zhu L . Human papillomavirus infection in Beijing, People's Republic of China: a population-based study. Br J Cancer. 2009; 101(9):1635-40. PMC: 2778508. DOI: 10.1038/sj.bjc.6605351. View

11.

Li L, Dai M, Clifford G, Yao W, Arslan A, Li N . Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer. 2006; 95(11):1593-7. PMC: 2360733. DOI: 10.1038/sj.bjc.6603450. View

12.

Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S . Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131(10):2349-59. DOI: 10.1002/ijc.27485. View

13.

Huh W, Ault K, Chelmow D, Davey D, Goulart R, Garcia F . Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015; 136(2):178-82. DOI: 10.1016/j.ygyno.2014.12.022. View

14.

Zhao F, Zhu F, Chen W, Li J, Hu Y, Hong Y . Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer. 2014; 135(11):2604-11. PMC: 4277334. DOI: 10.1002/ijc.28896. View

15.

Wu R, Dai M, Qiao Y, Clifford G, Liu Z, Arslan A . Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer. 2007; 121(6):1306-11. DOI: 10.1002/ijc.22726. View

16.

Chen W, Zhang X, Molijn A, Jenkins D, Shi J, Quint W . Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009; 20(9):1705-13. DOI: 10.1007/s10552-009-9422-z. View

17.

Guo F, Hirth J, Berenson A . Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccin Immunother. 2015; 11(10):2337-44. PMC: 4635939. DOI: 10.1080/21645515.2015.1066948. View

18.

Dong L, Hu S, Zhang Q, Feng R, Zhang L, Zhao X . Risk Prediction of Cervical Cancer and Precancers by Type-Specific Human Papillomavirus: Evidence from a Population-Based Cohort Study in China. Cancer Prev Res (Phila). 2017; 10(12):745-751. DOI: 10.1158/1940-6207.CAPR-17-0088. View

19.

Zeng Z, Yang H, Li Z, He X, Griffith C, Chen X . Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory. J Cancer. 2016; 7(9):1037-43. PMC: 4911869. DOI: 10.7150/jca.14971. View

20.

Gaarenstroom K, Melkert P, Walboomers J, van den Brule A, Van Bommel P, Meyer C . Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994; 4(2):73-78. DOI: 10.1046/j.1525-1438.1994.04020073.x. View